Shares of Devonian Health Group Inc. (CVE:GSD – Get Free Report) fell 8.4% during trading on Thursday. The stock traded as low as C$8.20 and last traded at C$8.20. Approximately 2,207 shares were traded during trading, an increase of 33% from the average daily volume of 1,662 shares. The stock had previously closed at C$8.95.
Devonian Health Group Stock Performance
The company has a market cap of C$22.80 million, a PE ratio of -3.64 and a beta of 0.03. The stock’s 50 day simple moving average is C$9.09 and its two-hundred day simple moving average is C$9.99. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
